How are HipSci cell lines to be acknowledged in any publication?

For any form of publication using HipSci cell lines, the MTA you would have completed to obtain the line, details the terms of acknowledgment. We have shown the terms for each cohort below.

Healthy cohort “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and the NIHR/Wellcome Trust Clinical Research Facility, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Bardet-Biedl syndrome “XXX acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), the NIHR Rare Diseases Translational Research Collaboration and the NIHR Great Ormond Street Hospital Biomedical Research Centre, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Alport syndrome (UCL) “XXX acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), UCL Centre for Nephrology and the Rosetrees Trust, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Alport syndrome (UoM) “XXX (recipient) acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and Manchester Academic Health Science Centre, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Hereditary Cerebellar Ataxia “XXX acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), the Medical Research Council (MRC UK), The Wellcome Trust (project and the Synaptopathies strategic award (104033)), The Brain Research Trust (BRT), Ataxia UK, The MSA Trust, The UK HSP Society and the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS), the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC), and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Congenital hyperinsulinia “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and the NIHR Rare Diseases Translational Research Collaboration and the NIHR Great Ormond Street Hospital Biomedical Research Centre, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Kabuki syndrome “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), Manchester Centre for Genomic Medicine, Central Manchester Foundation NHS Trust and University of Manchester, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Primary immune deficiency “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051). The line has been derived from a research participant in the NIHR BioResource -Rare Diseases study (https://bioresource.nihr.ac.uk/) which is funded by a grant from the NIHR, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Bleeding and platelet disorders “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051). The line has been derived from a research participant in the NIHR BioResource -Rare Diseases study (https://bioresource.nihr.ac.uk/) which is funded by a grant from the NIHR, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Hypertrophic cardiomyopathy “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and The Inherited Cardiovascular Unit at St Bartholomews’ Hospital, UCL Cardiovascular institute and the Randall institute at King’s College London, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Usher syndrome and congenital eye defects “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Monogenic Diabetes “XXX acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), where clinical samples were collected by Prof Andrew Hattersley and colleagues from the University of Exeter supported by the Wellcome Trust (098395), and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Batten disease “XXX (recipient of the line) acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and the UK Batten Disease Family Association, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Hereditary Spastic Paraplegia “XXX acknowledges Wellcome Trust Sanger Institute as the source of [cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051), the Medical Research Council (MRC UK), The Wellcome Trust (project and the Synaptopathies strategic award (104033)), The Brain Research Trust (BRT), Ataxia UK, The MSA Trust, The UK HSP Society and the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS), the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC), and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Retinitis Pigmentosa “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and the Fight for Sight, Moorfields Special Trustees, RP Fighting Blindness and the NIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Macular Dystrophy “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051) and the Fight for Sight, Moorfields Special Trustees, RP Fighting Blindness and the NIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”

Childhood Neurology “XXX acknowledges Wellcome Trust Sanger Institute as the source of [u- cell line name] human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust (WT098051). The line has been derived from a research participant in the NIHR BioResource -Rare Diseases study (https://bioresource.nihr.ac.uk/) which is funded by a grant from the NIHR, and acknowledges Life Science Technologies Corporation as the provider of Cytotune.”